Gilgamesh Pharmaceuticals

GM-2505 Clin1 depression, undisclosed; GM-200X Clin0 depression, undisclosed; GM-300X Clin0 opioid use disorder, undisclosed

Gilgamesh Pharmaceuticals is a clinical-stage neuroscience biotech company focused on developing innovative, rapid-acting, and long-lasting therapies for psychiatric disorders. Their research is centered on identifying and targeting the root causes of these conditions, rather than just managing symptoms. Gilgamesh has two lead clinical programs, GM-1020 and GM-2505, both in Phase 2 studies for major depressive disorder. The company is also developing a novel, cardiac-safe ibogaine analog for the treatment of opioid addiction. Gilgamesh developed a proprietary discovery platform that leverages artificial intelligence to systematically assess the bioactivity of psychoactive compounds and improve their translation to clinical use. It combines complex behavioral assessments, electrophysiology, and molecular measures of neuroplasticity to identify and design novel drug candidates.

Jobs: